Académique Documents
Professionnel Documents
Culture Documents
article info
abstract
Article history:
Keywords:
Ameloblastoma
Design: Eighty-two ameloblastoma samples and blood from 140 healthy controls were used
XRCC-1
Polymorphism
RFLP) for XRCC1 at codons 194, 280 and 399, and confirmed by sequence analysis.
Results: Compare to healthy control, a significant increase was noted in the occurrence of
polymorphism at codon 194 and 399 in ameloblastoma patients. At codon 194, tryptophan
encoded by T, was the susceptibility allele showed an ODD ratio of (95% CI) = 1.62 (1.052.48),
p = 0.027. At codon 399, glycine encoded by A was the susceptibility allele showing ODD ratio
of (95% CI) = 1.83 (1.192.84), p = 0.005. Moreover at codon 399, we found AG as the susceptibility genotype (2.06 (1.143.72), p = 0.015). However, we did not find any significant increase
in polymorphic occurrence in ameloblastoma patients at codon 280. For haplotype analysis
of 3 codons, we found GGC as protective haplotype, and AGT as the risk haplotype.
Conclusion: Our data suggest that polymorphism at codons 194 and 399, likely contributes to
the risk of developing ameloblastoma.
# 2012 Elsevier Ltd. All rights reserved.
1.
Introduction
* Corresponding author. Tel.: +66 2203 6470; fax: +66 2203 6470.
E-mail addresses: Nakarinkit@hotmail.com, Nakarinkit@gmail.com (N. Kitkumthorn).
00039969/$ see front matter # 2012 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.archoralbio.2012.10.016
584
2.
2.1.
140 healthy Thai populations, who matched to the ameloblastoma group with respect to age, sex and nationality.
Each ameloblastoma case underwent H&E histopathological evaluation prior to analysis, and those sections consisting
at least of 80% tumour cells were included in the study. For
analysis, 35 sections of 5 mM thick were collected in the
microtube underwent DNA isolation using the DNA QIAamp
DNA FFPE tissue (Qiagen, CA, USA). DNA from the peripheral
blood of each subject was extracted by proteinase K and
incubated overnight at 50 8C followed by phenol/chloroform
extraction and ethanol precipitation. Finally, the purified
genomic DNA was eluted and stored at 20 8C until needed for
use as a template in genotyping analysis.
2.2.
2.3.
Eighty-two paraffin embedded tissues, pathologically diagnosed with ameloblastoma were collected between 2002 and
2011, and obtained from the Faculty of Dentistry, Mahidol
University. Clinical and radiological data were obtained from
patients file. For the control group, subjects undergoing
routine health examination and those assessed to be free of
cancer were enrolled for the study. After obtaining written
informed consent, 6 mL of peripheral blood was collected from
XRCC1 genotyping
Statistical analysis
HardyWeinberg equilibrium calculator was used for assessing the consistency of genotype frequencies among normal
control. Allele and genotype frequency were compared
between patient and control groups. ODDS ratio (OR) and
95% confidence interval (CI) were used as parameters to
compare the frequency of SNP as risk factors in ameloblastoma. OR > 1 and 95% CI excluding 1 together with p value
<0.05 indicates a positive association or increase risk between
the SNP allele and ameloblastoma. Three SNPs were analysed
Table 1 Primer sequences, restriction enzymes and product sizes of PCRRFLP at XRCC1 codons 194, 280 and 399.
Codon (rs no.)
Primer sequence
194 (1799782)
Forward: AGAAGGTGACAGTGACCAAG
Reverse: ACGTTGTCCGAGCTCACCT
PvuII
Uncut: 131
Cut: 40 and 91
280 (25489)
Forward: TTGACCCCCAGTGGTGCT
Reverse: TGCCTTCTCCTCGGGGTTT
RsaI
Uncut: 133
Cut: 63 and 70
399 (25487)
Forward: CCCCAAGTACAGCCAGGTC
Reverse: CCCAGCACAGGATAAGGAGC
MspI
Uncut: 142
Cut: 48 and 94
585
for haplotype blocks. The PLINK v1.07 program21 was used for
performing the statistical analysis. Percentage of coefficient of
variance (% CV) was used to analyse the distribution of density
of the PCR band of each heterozygous sample to demonstrate
that there was no mosaisicm from the oral epithelium and
connective tissue (% CV 10, indicated that there was no
distribution of data).
3.
Results
3.1.
399
The genotypic data is summarized in Tables 24. Essentially, this study demonstrated that the frequency of Arg/Arg,
Trp/Trp and Arg/Trp genotype at codon 194, were 40.24%,
17.07% and 42.68%, respectively, in ameloblastomas.
Whereas in healthy controls, these were 52.86%, 8.57%
and 38.57%, respectively. At codon 280, the genotype Arg/
Arg, His/His and Arg/His were at a frequency of 70.73%,
3.66% and 25.61%, respectively, in ameloblastomas, and
73.57%, 4.29% and 22.14%, respectively, in healthy controls.
Finally at codon 399, the genotype Arg/Arg, Gln/Gln and
Arg/Gln were 32.93%, 12.20% and 54.88% in ameloblastomas, and 55.00%, 7.86% and 34.17%, respectively, in healthy
controls. The distribution of the genotype of codons 194, 280
and 399 among the controls was in the HardyWeinberg
equilibrium ( p > 0.05).
3.2.
Table 2 XRCC1 codon 194 polymorphisms in ameloblastoma patients and control subjects.
Groups
Controls
Sex
Male
Female
Ameloblastomas
Sex
Male
Female
Adjust OR
Clinical types
Unicystic type
Sex
Male
Female
Adjust OR
Conventional type
Sex
Male
Female
Adjust OR
No. of
samples
Ave.
age
Arg
Hetero
Trp
C/C
C/T
T/T
30.8
74 (52.86%)
54 (38.57%)
71 (50.71%)
69 (49.29%)
29.9
31.43
38 (53.52%)
36 (52.17%)
82
35.96
41 (50%)
41 (50%)
Allelic test
OR
(95% CI)
p value
12 (8.57%)
202 (72.14%)
78 (27.86%)
Ref.
27 (38.03%)
27 (39.13%)
6 (8.45%)
6 (8.70%)
103 (72.54%)
99 (71.74%)
39 (27.46%)
39 (28.26%)
Ref.
Ref.
33 (40.24%)
35 (42.68%)
14 (17.07%)
101 (61.59%)
63 (38.41%)
1.62 (1.052.48)
0.027
41.54
31.39
20 (48.78%)
13 (31.71%)
14 (34.15%)
21 (51.22%)
7 (17.07%)
7 (17.07%)
54 (65.85%)
47 (57.32%)
28 (34.15%)
35 (42.68%)
1.37 (0.732.57)
1.89 (1.023.49)
1.61 (1.052.48)
0.367
0.041
0.028
23
35.96
7 (30.44%)
13 (56.52%)
3 (13.04%)
27 (58.70%)
19 (41.30%)
1.82 (0.913.63)
0.093
12 (52.17%)
11 (47.83%)
41.54
31.39
4 (33.33%)
3 (27.27%)
7 (58.34%)
6 (54.55%)
1 (8.33%)
2 (18.18%)
15 (62.50%)
12 (54.55%)
9 (37.50%)
10 (45.45%)
1.58 (0.584.25)
2.12 (0.775.79)
1.83 (0.913.63)
0.447
0.168
0.094
26 (44.07%)
22 (37.29%)
11 (18.64%)
74 (62.71%)
44 (37.29%)
1.54 (0.952.49)
0.081
15 (51.72%)
11 (36.67%)
8 (27.59%)
14 (46.67%)
6 (20.69%)
5 (16.66%)
38 (65.52%)
36 (60.00%)
20 (34.48%)
24 (40.00%)
1.39 (0.692.81)
1.69 (0.853.35)
1.54 (0.952.49)
0.414
0.143
0.082
140
59
29 (49.15%)
30 (50.85%)
41.54
31.39
586
Table 3 XRCC1 codon 280 polymorphisms in ameloblastoma patients and control subjects.
Groups
No. of
samples
Ave.
age
Arg
Controls
Sex
Male
Female
Ameloblastomas
Sex
Male
Female
Adjust OR
Clinical types
Unicystic type
Sex
Male
Female
Adjust OR
Conventional type
Sex
Male
Female
Adjust OR
Hetero
His
Allelic test
OR
(95% CI)
p value
G/G
G/A
A/A
30.8
103 (73.57%)
31 (22.14%)
6 (4.29%)
237 (84.64%)
43 (15.36%)
Ref.
71 (50.71%)
69 (49.29%)
29.9
31.43
56 (78.87%)
47 (68.12%)
11 (15.49%)
20 (28.99%)
4 (5.63%)
2 (2.90%)
123 (86.62%)
114 (82.61%)
19 (13.38%)
24 (17.39%)
Ref.
Ref.
82
35.96
58 (70.73%)
21 (25.61%)
3 (3.66%)
137 (83.54%)
27 (16.46%)
1.09 (0.621.89)
0.862
41 (50%)
41 (50%)
41.54
31.39
29 (70.73%)
29 (70.73%)
9 (21.95%)
12 (29.27%)
3 (7.32%)
0 (0.00%)
67 (81.71%)
70 (85.37%)
15 (18.29%)
12 (14.63%)
1.45 (0.653.22)
0.81 (0.361.83)
1.09 (0.621.89)
0.427
0.729
0.864
23
35.96
15 (65.22%)
7 (30.43%)
1 (4.35%)
37 (80.43%)
9 (19.57%)
1.34 (0.563.15)
0.613
12 (52.17%)
11 (47.83%)
41.54
31.39
9 (75.00%)
6 (54.55%)
2 (16.67%)
5 (45.45%)
1 (8.33%)
0 (0.00%)
20 (83.33%)
17 (77.27%)
4 (16.67%)
5 (22.73%)
1.29 (0.334.63)
1.40 (0.404.57)
1.35 (0.563.17)
0.911
0.76
0.606
43 (72.88%)
14 (23.73%)
2 (3.39%)
100 (84.75%)
18 (15.25%)
0.99 (0.521.87)
0.899
19 (65.52%)
24 (80.00%)
8 (27.59%)
6 (20.00%)
2 (6.89%)
0 (0.00%)
46 (79.31%)
54 (90.00%)
12 (20.69%)
6 (10.00%)
1.69 (0.714.01)
0.53 (0.181.46)
0.99 (0.521.87)
0.279
0.263
0.898
140
59
29 (49.15%)
30 (50.85%)
41.54
31.39
Table 4 XRCC1 codon 399 polymorphisms in ameloblastoma patients and control subjects.
Groups
Controls
Sex
Male
Female
Ameloblastomas
Sex
Male
Female
Adjust OR
Clinical types
Unicystic type
Sex
Male
Female
Adjust OR
Conventional type
Sex
Male
Female
Adjust OR
No. of
samples
140
Ave.
age
30.8
Hetero
Gln
G/G
G/A
A/A
82
0.005
41 (50%)
41 (50%)
4 (9.76%)
6 (14.63%)
0.015
0.154
0.005
23
35.96
8 (34.78%) 15 (65.22%)
0 (0.00%)
0.488
5 (41.67%)
4 (36.36%)
0 (0.00%)
0 (0.00%)
17 (70.83%)
15 (68.18%)
0.435
0.917
0.677
12 (52.17%) 41.54
11 (47.83%) 31.39
59
29 (49.15%) 41.54
30 (50.85%) 31.39
7 (58.33%)
7 (63.64%)
4 (13.79%)
6 (20.00%)
0.002
0.002
0.104
0.001
587
Genotype
OR (95% CI)
p value
194
TT
CT
2.20 (0.95.41)
1.19 (0.662.14)
0.092
0.645
280
AA
GA
0.85 (0.163.96)
1.21 (0.612.40)
0.901
0.671
399
AA
AG
1.63 (0.614.37)
2.06 (1.143.72)
0.407
0.015
3.3.
Haplotype analysis
3.4.
Model of inheritance
3.5.
Distribution of PCR density band of heterozygous
samples
To confirm that there was no mosaisicm from the oral
epithelium and adjacent connective tissue, we randomly
AAT
GAT
AGT
GGT
AAC
GAC
AGC
GGC
Haplotype frequency
Ameloblastomas
Healthy controls
NA
0.0302
0.1037
0.2502
0.0274
0.1071
0.2653
0.2162
NA
0.0273
0.0287
0.2226
0.0166
0.1097
0.219
0.3761
p value
0.0022
0.8581
0.0009
0.5063
0.4401
0.9315
0.2681
0.0005
Standard
deviation
Coefficient of
variance (%)
66.7
19.58
13.71
1.7
1.64
1.35
2.55
8.36
9.85
34.09
33.2
32.7
1.38
2.13
2.49
4.04
6.4
7.61
37.81
32.19
30
1.29
1.3
1.95
3.4
4.05
6.51
Codon 194
C band
T band at 91 b.p.
T band at 40 b.p.
Codon 280
A band
G band at 70 b.p.
G band at 63 b.p.
Codon 399
A band
G band at 94 b.p.
G band at 48 b.p.
4.
Discussion
588
Funding
This study was financially supported by Research Chair Grant
2011 from the National Science and Technology Development
Agency (NSTDA), Thailand, TRF-MRG young scientific researcher grant No. MRG 5380010, and research fund from the
Faculty of Science, Chulalongkorn University.
Competing interests
The authors declare that they have no conflict of interest.
Ethical approval
The research protocol was approved by the Institutional
Review Board of the Faculty of Medicine, Chulalongkorn
University (IRB 093/54).
Acknowledgements
The authors thank Mr. Dusit Bumalee for help in preparing the
tissue samples and Dr. Viomesh Patel (NIDCR/NIH) for
critically reviewing the manuscript.
references
1. Fernandes AM, Duarte EC, Pimenta FJ, Souza LN, Santos VR,
Mesquita RA, et al. Odontogenic tumors: a study of 340 cases
in a Brazilian population. Journal of Oral Pathology and
Medicine 2005;34(10):5837.
2. Ladeinde AL, Ajayi OF, Ogunlewe MO, Adeyemo WL, Arotiba
GT, Bamgbose BO, et al. Odontogenic tumors: a review of 319
cases in a Nigerian teaching hospital. Oral Surgery Oral
Medicine Oral Pathology Oral Radiology and Endodontics
2005;99(2):1915.
3. Luo HY, Li TJ. Odontogenic tumors: a study of 1309 cases
in a Chinese population. Oral Oncology 2009;45(8):
70611.
4. Ebenezer V, Ramalingam B. A cross-sectional survey of
prevalence of odontogenic tumours. Journal of Maxillofacial
and Oral Surgery 2010;9(4):36974.
5. Osterne RL, Brito RG, Alves AP, Cavalcante RB, Sousa FB.
Odontogenic tumors: a 5-year retrospective study
in a Brazilian population and analysis of 3406 cases
reported in the literature. Oral Surgery Oral Medicine Oral
Pathology Oral Radiology and Endodontics 2011;111(4):
47481.
6. Barnes L, Reichart EJ, Sidransky PD. World Health Organization
classification of tumours. Pathology and genetics of head and neck
tumours. Lyon: IARC Press; 2005.
7. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS,
Mendenhall NP. Ameloblastoma. American Journal of Clinical
Oncology 2007;30(6):6458.
8. Reichart PA, Philipsen HP, Sciubba JJ. The new classification
of head and neck tumours (WHO)any changes? Oral
Oncology 2006;42(8):7578.
9. Carlson ER, Marx RE. The ameloblastoma: primary, curative
surgical management. Journal of Oral and Maxillofacial Surgery
2006;64(3):48494.
10. Eckardt AM, Kokemuller H, Flemming P, Schultze A.
Recurrent ameloblastoma following osseous
reconstructiona review of twenty years. Journal of CranioMaxillo-Facial Surgery 2009;37(1):3641.
11. Abiko Y, Nagayasu H, Takeshima M, Yamazaki M,
Nishimura M, Kusano K, et al. Ameloblastic carcinoma
ex ameloblastoma: report of a case-possible involvement
of CpG island hypermethylation of the p16 gene in
malignant transformation. Oral Surgery Oral Medicine Oral
Pathology Oral Radiology and Endodontics 2007;103(1):
726.
12. Hoeijmakers JH. Genome maintenance mechanisms for
preventing cancer. Nature 2001;411(6835):36674.
13. Li Y, Marion MJ, Zipprich J, Freyer G, Santella RM, Kanki C,
et al. The role of XRCC1 polymorphisms in base excision
repair of etheno-DNA adducts in French vinyl chloride
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
589